Published in J Neurochem on January 29, 2009
Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism. Front Behav Neurosci (2016) 1.44
Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res (2010) 1.13
Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death. Neuropsychopharmacology (2010) 1.10
Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol (2010) 1.07
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2009) 0.98
Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation (2013) 0.95
Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br J Pharmacol (2009) 0.92
Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol (2009) 0.89
GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. Front Neuroanat (2015) 0.87
Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of corticostriatal glutamatergic transmission. Br J Pharmacol (2015) 0.82
Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum. Br J Pharmacol (2013) 0.79
Dysregulation of brain adenosine is detrimental to the expression of conditioned freezing but not general Pavlovian learning. Pharmacol Biochem Behav (2013) 0.77
Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and Anxiety. Front Psychiatry (2014) 0.76
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med (1994) 6.77
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci (2007) 3.64
Novel functions and signalling pathways for GDNF. J Cell Sci (2003) 2.98
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature (1995) 2.69
Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci (2002) 2.40
Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 2.35
Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci (2001) 2.29
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol (2007) 1.90
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol (2005) 1.86
Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol (1999) 1.76
Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol (2007) 1.72
Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol (2006) 1.49
Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci (2007) 1.48
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol (2008) 1.34
The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther (1996) 1.30
Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci (2004) 1.19
Huntington's disease: a synaptopathy? Trends Mol Med (2003) 1.16
Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci U S A (2007) 1.12
Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem (2005) 1.11
Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience (2002) 1.09
Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J Neurosci (2006) 1.08
Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience (2005) 1.08
Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology (2008) 0.99
Neurotrophic factors in Huntington's disease. Prog Brain Res (2004) 0.96
Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus (2007) 0.94
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol (2007) 0.94
Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience (2001) 0.93
Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci Lett (2006) 0.92
Continuing trials of GDNF in Parkinson's disease. Lancet Neurol (2006) 0.90
Dopamine neurons in a simple GDNF-treated meso-striatal organotypic co-culture model. Exp Brain Res (1999) 0.89
Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. J Neurosci (2008) 0.88
Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. Eur J Neurosci (2003) 0.87
Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner. Brain Res (2006) 0.87
Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J Integr Neurosci (2005) 0.86
Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. J Neurosci (2006) 0.83
The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol (2004) 0.81
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods (2008) 2.10
Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron (2008) 2.09
Adenosine and brain function. Int Rev Neurobiol (2005) 1.97
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Amazing stability of the arginine-phosphate electrostatic interaction. J Proteome Res (2005) 1.75
Circadian-related heteromerization of adrenergic and dopamine D₄ receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biol (2012) 1.69
Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem (2004) 1.63
Adenosine receptors and the central nervous system. Handb Exp Pharmacol (2009) 1.53
Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des (2010) 1.50
Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav (2007) 1.48
Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Sci Transl Med (2013) 1.46
Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology (2008) 1.45
Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev (2003) 1.45
Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. J Neurosci (2008) 1.41
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A (2010) 1.35
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta (2010) 1.32
Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem (2008) 1.30
Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci (2005) 1.29
Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology (2007) 1.28
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem (2004) 1.27
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26
Caffeine and adenosine. J Alzheimers Dis (2010) 1.25
Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol (2009) 1.25
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Basic concepts in G-protein-coupled receptor homo- and heterodimerization. ScientificWorldJournal (2007) 1.24
Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem (2009) 1.23
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol (2006) 1.23
Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci (2009) 1.23
Adenosine receptor heteromers and their integrative role in striatal function. ScientificWorldJournal (2007) 1.22
Role of electrostatic interaction in receptor-receptor heteromerization. J Mol Neurosci (2005) 1.22
Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One (2011) 1.20
Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci (2002) 1.20
Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal (2009) 1.16
Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem (2004) 1.15
Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem (2010) 1.15
Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology (2008) 1.15
Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem (2011) 1.15
Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci (2012) 1.13
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des (2008) 1.13
Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci (2005) 1.12
Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem (2004) 1.12
Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem (2005) 1.11
Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol (2005) 1.10
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Dimer-based model for heptaspanning membrane receptors. Trends Biochem Sci (2005) 1.07
Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol (2010) 1.07
Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci (2003) 1.06
GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol Ther (2009) 1.06
Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem (2007) 1.05
Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem (2003) 1.04
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl) (2005) 1.03
Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov (2007) 1.02
Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem (2010) 1.02
Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors. J Biol Chem (2009) 1.02
Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol (2003) 1.01
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging (2011) 1.01
Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci (2012) 1.01
Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem (2010) 0.99
The two-state dimer receptor model: a general model for receptor dimers. Mol Pharmacol (2006) 0.99
Blockade of adenosine A(2A) receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis (2007) 0.97
Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. J Neurochem (2009) 0.97
Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index. Pharmacol Ther (2007) 0.97
Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett (2002) 0.97
Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One (2012) 0.96
Subcellular localization of adenosine A(1) receptors in nerve terminals and synapses of the rat hippocampus. Brain Res (2003) 0.96
Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cereb Cortex (2012) 0.95
Neuronal P2 receptors of the central nervous system. Curr Top Med Chem (2004) 0.95
Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology (2006) 0.95
Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport (2003) 0.95
Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation (2013) 0.95
Oligomerization of G-protein-coupled receptors: a reality. Curr Opin Pharmacol (2009) 0.95
Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology (2011) 0.94
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci (2013) 0.94
Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice. Br J Pharmacol (2004) 0.94
Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus (2007) 0.94
Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochim Biophys Acta (2008) 0.94
Early changes of neuromuscular transmission in the SOD1(G93A) mice model of ALS start long before motor symptoms onset. PLoS One (2013) 0.94
Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia (2012) 0.93
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) (2005) 0.93
Light resonance energy transfer-based methods in the study of G protein-coupled receptor oligomerization. Bioessays (2008) 0.93
Lack of evidence for functional TRPV1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci Lett (2006) 0.93
Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function. Front Neuroanat (2011) 0.93
Adenosine: setting the stage for plasticity. Trends Neurosci (2013) 0.92